Table 5 Clinicopathologic studies of ASPS
From: Alveolar soft part sarcoma: progress toward improvement in survival? A population-based study
Source | No. of patients (localized/metastatic) | 5-year survival | Prognostic factor | Comments | ||
|---|---|---|---|---|---|---|
Overall | Localized | Metastatic | ||||
Lieberman et al., 1989 [4] | 91 (69/22) | 57% | 60% | 22% | Age, metastasis | Increased rate of metastasis at presentation as the age increases |
Casanova et al., 2000 [9] | 19 (15/4) | 80% | 91% | NA | Size | Series of pediatric patients (median age, 12Â years) |
Portea et al., 2001Â [2] | 74 (22/52) | 47% | 88% | 20% | Metastasis | Brain metastasis in 9 of 48 patients (18.8%) with metastatic disease |
Ogose et al., 2003 [5] | 57 (20/37) | 56% | 81% | 46% | Size, metastasis, bone involvement | Bone involvement at the primary site in 23% |
Daigeler et al., 2008 [32] | 11 (11/0) | 88% | 88% | – | None | Brain and lung metastasis in 3 of 3 patients (100%) who developed metastases |
Ogura et al., 2012 [16] | 26 (10/16) | 64% | 100% | 37% | Size, metastasis | Median survival, 90Â months |
Wang et al., 2016 [3] | 251 (118/108) | 56% | 81% | 41% (surgery +), 10% (surgery-) | Age, size, metastasis, trunk, no treatment, RT without surgery | Improved OS with surgery + RT (localized) Improved OS with surgery of primary site (metastatic) |
Brennan et al., 2018 [33] | 22 (20/2) | 100% | 100% | 100% | NA | Series of pediatric patients (median age, 11.5Â years) 5-year EFS, 94.7% (localized disease) |
Flores et al., 2018 [31] | 69 (31/38) | 72% | 87% | 61% | Age, sex, metastasis | Series of pediatric patients (< 30 years) |
Hagerty et al., 2020 [17] | 293 (83/172) | NA | 73% (surgery +) | 46% (surgery +) | Size, margin, metastasis, multimodal therapy, hospital volume | Analysis from National Cancer Database in the United States |
Current study, 2022 | 120 (34/86) | 68% | 86% | 62% | Metastasis | Analysis from BSTTR Database in Japan |